for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aytu Bioscience Inc

AYTU.OQ

Latest Trade

1.29USD

Change

-0.01(-0.39%)

Volume

74,367

Today's Range

1.28

 - 

1.30

52 Week Range

0.34

 - 

2.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.29
Open
1.30
Volume
74,367
3M AVG Volume
163.44
Today's High
1.30
Today's Low
1.28
52 Week High
2.99
52 Week Low
0.34
Shares Out (MIL)
120.26
Market Cap (MIL)
155.14
Forward P/E
-6.39
Dividend (Yield %)
--

Next Event

Q4 2020 Aytu BioScience Inc Earnings Release

Latest Developments

More

Aytu Bioscience Announces Emergency Use Authorization Of COVID-19 IgG/IgM Rapid Test

Aytu Bioscience Posts Quarterly Revenue $8.2 Million

Biolidics Appoints Aytu Bioscience As Exclusive Distributor For Rapid Test Kits For Coronavirus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aytu Bioscience Inc

Aytu BioScience, Inc. is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The primary care portfolio includes Natesto, the nasal formulation of testosterone for men with hypogonadism, ZolpiMist, the oral spray prescription sleep aid, and Tuzistra XR, the 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; Cefaclor, a second-generation cephalosporin antibiotic suspension; Karbinal ER, an extended-release carbinoxamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency.

Industry

Biotechnology & Drugs

Contact Info

373 Inverness Pkwy Ste 206

ENGLEWOOD, CO

80112-5898

United States

+1.720.4376580

http://aytubio.com/

Executive Leadership

Joshua R. Disbrow

Chairman of the Board, Chief Executive Officer

David A. Green

Chief Financial Officer, Treasurer, Secretary

Jarrett T. Disbrow

Chief Operating Officer

Matthew V. Phillips

Executive Vice President - Commercial Operations

Steven J. Boyd

Independent Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-966.000

2019

-2.220

2020(E)

-0.220
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.71
Price To Book (MRQ)
1.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-33.18
Return on Equity (TTM)
-25.35

Latest News

Latest News

BRIEF-Aytu Bioscience Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing

* AYTU BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING Source text for Eikon: https://bit.ly/2Yaai4K Further company coverage:

BRIEF-Aytu Bioscience Announces $15 Mln Debt Retirement

* AYTU BIOSCIENCE ANNOUNCES $15 MILLION DEBT RETIREMENT Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Announces Emergency Use Authorization Of COVID-19 IgG/IgM Rapid Test

* AYTU BIOSCIENCE ANNOUNCES EMERGENCY USE AUTHORIZATION OF COVID-19 IGG/IGM RAPID TEST

BRIEF-Aytu Bioscience Posts Quarterly Revenue $8.2 Million

* AYTU BIOSCIENCE INC - REPORTS REVENUE FOR THREE MONTHS ENDED MARCH 31, 2020 OF $8.2 MILLION, UP 243% YEAR-OVER-YEAR

BRIEF-Aytu Bioscience Announces China Export Clearance Of Company's Covid-19 IgG/IgM Rapid Test

* AYTU BIOSCIENCE ANNOUNCES CHINA EXPORT CLEARANCE OF COMPANY'S COVID-19 IGG/IGM RAPID TEST

BRIEF-Aytu Bioscience Has Rescheduled Upcoming Annual Meeting Of Stockholders To April 23

* AYTU BIOSCIENCE - HAS RESCHEDULED UPCOMING ANNUAL MEETING OF STOCKHOLDERS TO APRIL 23 Source text for Eikon: Further company coverage:

BRIEF-Armistice Capital Reports 5.3% Stake In Aytu Bioscience

* ARMISTICE CAPITAL LLC REPORTS 5.3% STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 20 - SEC FILING

BRIEF-Aytu Bioscience Reports Cash Balance Of $62.5 Mln As Of March 31, 2020

* AYTU BIOSCIENCE INC - ANNOUNCED A CASH BALANCE (UNAUDITED) OF APPROXIMATELY $62.5 MILLION AS OF MARCH 31, 2020 Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Began Shipping Its Coronavirus Disease 2019 Igg/Igm Rapid Test To U.S. Customers

* AYTU BIOSCIENCE INC - BEGAN SHIPPING ITS CORONAVIRUS DISEASE 2019 ("COVID-2019") IGG/IGM RAPID TEST TO U.S. CUSTOMERS

BRIEF-Aytu Bioscience Has Received Its First Coronavirus Disease 2019 Igg/Igm Rapid Test Shipment Containing 100,000 Tests From Manufacturer On March 31

* AYTU BIOSCIENCE - HAS RECEIVED ITS FIRST CORONAVIRUS DISEASE 2019 IGG/IGM RAPID TEST SHIPMENT CONTAINING 100,000 TESTS FROM MANUFACTURER ON MARCH 31

BRIEF-Aytu Bioscience Received Confirmation From U.S. FDA That Co May Begin Distribution Of Its Coronavirus Disease 2019 IGG/IGM Rapid Test Throughout U.S.

* AYTU BIOSCIENCE - RECEIVED CONFIRMATION FROM U.S. FDA THAT CO MAY BEGIN DISTRIBUTION OF ITS CORONAVIRUS DISEASE 2019 IGG/IGM RAPID TEST THROUGHOUT U.S.

BRIEF-Aytu Bioscience Announces Acceleration Of U.S. Availability Of Covid-19 Igg/Igm Rapid Test

* AYTU BIOSCIENCE INC - ANNOUNCES ACCELERATION OF U.S. AVAILABILITY OF COVID-19 IGG/IGM RAPID TEST BASED ON UPDATED FDA POLICY

BRIEF-Armistice Capital Cuts Stake In Aytu BioScience To 9.1% From 40%

* ARMISTICE CAPITAL, LLC CUTS STAKE TO 9.1% IN AYTU BIOSCIENCE AS OF MARCH 10 FROM STAKE OF 40% AS OF FEB 14 - SEC FILING Source: (http://bit.ly/33fRao4) Further company coverage:

BRIEF-Sabby Management Llc Reports 9.75% Passive Stake In Aytu Bioscience

* SABBY MANAGEMENT LLC REPORTS 9.75% PASSIVE STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 12, 2020 - SEC FILING Source text : (http://bit.ly/38E2Dio) Further company coverage:

BRIEF-Aytu Bioscience Q3 Loss Per Share $0.24

* AYTU BIOSCIENCE PROVIDES FISCAL THIRD QUARTER 2018 BUSINESS UPDATE

BRIEF-Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2

* BIGGER CAPITAL FUND L P REPORTS A 7.4 PERCENT PASSIVE STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 2 - SEC FILING Source text: (http://bit.ly/2HiWvi8) Further company coverage:

BRIEF-Aytu Bioscience Gets Market Registration For The Mioxsys System For Male Infertility In Mexico

* AYTU BIOSCIENCE RECEIVES MARKET REGISTRATION FOR THE MIOXSYS® SYSTEM FOR MALE INFERTILITY IN MEXICO Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Announces Pricing Of $12 Mln Public Offering

* AYTU BIOSCIENCE ANNOUNCES PRICING OF $12,000,000 PUBLIC OFFERING

BRIEF-Aytu BioScience Provides Update On The Continued Growth Of Natesto In The U.S.

* AYTU BIOSCIENCE PROVIDES UPDATE ON THE CONTINUED GROWTH OF NATESTO® IN THE U.S. Source text for Eikon: Further company coverage:

BRIEF-Aytu Bioscience Q2 Revenue $1.1 Mln, An Increase Of 32 pct

* AYTU BIOSCIENCE INC - TOTAL REVENUE FOR Q2 WAS ABOUT $1.1 MILLION, AN INCREASE OF 32%

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up